Medicine and Dentistry
Interstitial Lung Disease
100%
Idiopathic Pulmonary Fibrosis
72%
Lung
51%
COVID-19
42%
Placebo
34%
Pulmonary Fibrosis
33%
Forced Vital Capacity
28%
Diseases
22%
Pirfenidone
21%
Clinical Trial
20%
Nintedanib
18%
Coughing
16%
Silo-Filler's Disease
15%
Rheumatoid Arthritis
14%
Inflammatory Arthritis
14%
Dyspnea
14%
Biological Marker
12%
Adverse Event
11%
Morphine
10%
Volatile Organic Compound
9%
Sequela
9%
Metabolite
9%
Cancer Growth Factor
9%
Infection
9%
Magnetic Resonance Imaging
8%
Sarcoidosis
8%
Patient Referral
6%
Observational Study
6%
Disease Exacerbation
6%
Lung Function
6%
Cohort Analysis
6%
Intensive Care Unit
6%
Immunosuppressive Treatment
5%
Rheumatology
5%
Patient Care
5%
Chronic Obstructive Pulmonary Disease
5%
In Vitro
5%
Spirometry
5%
Immunosuppressive Drug
5%
Post-COVID-19
5%
Cross Sectional Study
5%
Lung Biopsy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrosing Alveolitis
52%
Interstitial Lung Disease
43%
Nintedanib
38%
Placebo
35%
Lung Fibrosis
25%
Pirfenidone
24%
Tolerability
17%
Adverse Event
16%
Rheumatoid Arthritis
14%
Inflammatory Arthritis
14%
Diseases
14%
Clinical Trial
14%
Coughing
13%
Observational Study
11%
Morphine
10%
Volatile Organic Compound
9%
Cancer Growth Factor
9%
Dyspnea
8%
Lung Disease
8%
Infection
8%
Biological Marker
8%
Pandemic
7%
Respiratory Tract Disease
7%
Disease Exacerbation
5%
Prevalence
5%